藥物交互作用
Betibeglogene autotemcel + Deferoxamine
嚴重程度: 嚴重
Betibeglogene autotemcel and Deferoxamine: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Some iron chelators can suppress bone marrow and may interfere with engraftment and hematologic recovery after gene therapy conditioning. Chelation around the time of myeloablation and infusion is therefore restricted.
用白話說明這項交互作用的意義
Betibeglogene autotemcel and Deferoxamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
為什麼會發生
Potential additive myelosuppressive or marrow-impairing effects of chelators could compromise engraftment; deferoxamine itself is less myelosuppressive than some chelators, so the mechanism is not firmly established.
處置方式
Stop iron chelation at least 7 days before conditioning, and avoid myelosuppressive chelators for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron reduction is needed.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Deferoxamine 的其他交互作用
常見問題
Can I take Betibeglogene autotemcel with Deferoxamine?
MediHelp rates the interaction as major. Betibeglogene autotemcel and Deferoxamine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Some iron chelators can suppress bone marrow and may interfere with engraftment and hematologic recovery after gene therapy conditioning. Chelation around the time of myeloablation and infusion is therefore restricted.
How serious is the interaction between Betibeglogene autotemcel and Deferoxamine?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Stop iron chelation at least 7 days before conditioning, and avoid myelosuppressive chelators for about 6 months after infusion. Use phlebotomy or a non-myelosuppressive chelator if iron reduction is needed.
What other medicines interact with Deferoxamine?
MediHelp also lists interactions of Deferoxamine with, for example, Ascorbic acid, Exagamglogene autotemcel, Lovotibeglogene autotemcel. The full list is on the Deferoxamine page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
